Chemotherapy Regimens for HER2-Negative Breast Cancer

Guideline-Based Hierarchy

The National Comprehensive Cancer Network (NCCN) guidelines establish a clear hierarchy, with dose-dense AC followed by paclitaxel, dose-dense AC followed by weekly paclitaxel, and TC (docetaxel and cyclophosphamide) as top-tier preferred regimens for HER2-negative disease 1, 2, 3, 4, 5, 6
All three regimens hold equal "preferred" status in the 2014 NCCN guidelines, meaning they are all Category 1 recommendations when used in the adjuvant setting 1, 2, 3

The addition of sequential taxane to AC improves disease-free survival compared to AC alone 1, 2, 3
The ECOG E1199 trial showed weekly paclitaxel after AC was superior to every-3-weekly paclitaxel in both disease-free survival (HR 1.27, P=0.006) and overall survival (HR 1.32, P=0.01) 7, 8, 9
For triple-negative breast cancer specifically, 10-year DFS with weekly paclitaxel was 69% and OS was 75% 10

The NCCN recommends using ACT (sequential AC followed by taxane) as first-line for node-positive disease requiring maximum efficacy, high-risk node-negative disease, and triple-negative breast cancer where maximum benefit is needed 1, 2, 3, 7, 10
Dose-dense AC followed by weekly paclitaxel provides optimal outcomes 1, 2, 7, 8, 9
Dose-dense AC followed by paclitaxel every 2 weeks is equally preferred 1, 2, 3

ACT regimens carry a risk of cardiac toxicity from anthracyclines (monitor LVEF) 1, 2
Dose-dense schedules require growth factor support 8, 9
TC regimen has no cardiac toxicity, but higher rates of febrile neutropenia and more myalgia, arthralgia, and edema 8, 9

All regimens listed for HER2-negative disease are Category 1 recommendations in the adjuvant setting 1, 2, 3
Retrospective evidence suggests anthracycline-based regimens may be superior in HER2-positive tumors 1, 2, 3
Chemotherapy benefits are greater in ER-negative disease (22.8% absolute benefit vs 7% in ER-positive) 7, 8, 9
Chemotherapy and endocrine therapy should be given sequentially, with endocrine therapy after chemotherapy 1, 2, 10

The National Comprehensive Cancer Network guidelines establish the TAC protocol, which includes doxorubicin 50 mg/m² IV on day 1, and all cycles require filgrastim (G-CSF) support, for patients with breast cancer 11, 12

The National Comprehensive Cancer Network lists TAC as a preferred adjuvant regimen for HER2-negative breast cancer, though it has been somewhat superseded by dose-dense AC followed by taxane regimens in more recent guidelines 13, 14

The every-3-week schedule with mandatory G-CSF support is non-negotiable due to significant hematologic toxicity, as stated by the National Comprehensive Cancer Network 11, 12

The American Society of Clinical Oncology recommends a 4-week interval (every 3 weeks) for the docetaxel-doxorubicin-cyclophosphamide (TAC) regimen, administered for 6 cycles with mandatory G-CSF support 15, 16
The TAC regimen consists of docetaxel 75 mg/m², doxorubicin 50 mg/m², and cyclophosphamide 600 mg/m² administered intravenously every 3 weeks (21-day cycles) for 6 cycles, and has demonstrated superiority over fluorouracil-doxorubicin-cyclophosphamide × 6 in clinical trials 15, 16

The American Society of Clinical Oncology explicitly lists docetaxel-doxorubicin-cyclophosphamide × 6 as one of the recommended adjuvant chemotherapy regimens for early breast cancer, particularly for high-risk patients 15, 16

The docetaxel-cyclophosphamide (TC) regimen consists of docetaxel 75 mg/m² and cyclophosphamide 600 mg/m² every 21 days for 4 cycles, and is recommended as an alternative to AC × 4, offering improved disease-free survival and overall survival 15, 16

Grade 3/4 neutropenia occurs in 63.3% of patients with TAC regimens, and febrile neutropenia occurs in approximately 9.3% of patients despite G-CSF support 17
The cumulative dose of doxorubicin should not exceed 240 mg/m² in two-drug regimens 15, 16

The American Society of Clinical Oncology recommends against extending the TAC regimen to a 4-week (28-day) cycle interval, as the evidence base and guideline recommendations are specifically for every-3-week administration 15, 16